Biodesix CAO sells 101 shares after RSU vesting

Biodesix, Inc. Chief Accounting Officer Chris Vazquez reported equity award activity and a small share sale.

Rhea-AI Filing Summary

Biodesix, Inc. Chief Accounting Officer Chris Vazquez reported equity award activity and a small share sale. On February 9, 2026, RSUs were converted into 263 shares of Common Stock, increasing direct holdings to 1,335 shares, and RSU positions were adjusted following a one-for-twenty reverse split.

On February 10, 2026, Vazquez executed an open‑market sale of 101 Common shares at a weighted average price of $10.0841, conducted automatically to cover taxes upon RSU vesting, leaving 1,234 Common shares held directly and 234 RSUs outstanding, which vest over time subject to continued service.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Vazquez Chris

Role Chief Accounting Officer

Sold 101 shs ($1K)

Approx. gross sale proceeds $1K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock	101	$10.0841	$1K
Exercise	Restricted Stock Units	28	$0.00	$0.00
Exercise	Restricted Stock Units	235	$0.00	$0.00
Exercise	Common Stock	263	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 234 contracts (Direct); Common Stock — 1,234 shares (Direct)

Footnotes (6)

1. F1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
2. F2. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
3. F3. The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. F4. These RSUs vested in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and had no expiration date.
5. F5. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.
6. F6. These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Biodesix (BDSX) report for Chris Vazquez?

Biodesix reported that Chief Accounting Officer Chris Vazquez converted RSUs into 263 Common shares on February 9, 2026 and then sold 101 Common shares on February 10, 2026. The sale was conducted to cover taxes arising from the RSU vesting.

How many Biodesix (BDSX) shares did the CAO sell and at what price?

Chris Vazquez sold 101 shares of Biodesix Common Stock at a weighted average price of $10.0841 per share. The shares were sold in multiple transactions between $9.94 and $10.21 to cover tax obligations triggered by restricted stock unit vesting.

How many Biodesix (BDSX) shares does the CAO own after the reported Form 4?

After the reported transactions, Chris Vazquez directly owns 1,234 shares of Biodesix Common Stock. These holdings reflect RSU conversions on February 9, 2026 and the subsequent 101‑share sale on February 10, 2026 to satisfy tax withholding requirements.

What RSU activity did Biodesix (BDSX) disclose for Chris Vazquez?

Biodesix disclosed that restricted stock units for Chris Vazquez were exercised into 28 and 235 underlying Common shares on February 9, 2026. Following the transactions, 234 RSUs remain outstanding, vesting in scheduled installments tied to continued service with the company.

How did Biodesix (BDSX) reverse stock split affect the CAO’s RSUs?

The numbers for Chris Vazquez’s RSUs were adjusted to reflect Biodesix’s one‑for‑twenty reverse stock split effective September 15, 2025. This adjustment changed the reported RSU and share counts but did not alter the economic value of his underlying equity awards.

Were Chris Vazquez’s Biodesix (BDSX) share sales discretionary?

The 101 Biodesix shares sold by Chris Vazquez were not discretionary sales for investment purposes. They were automatically sold by the company’s broker to cover taxes due upon vesting of restricted stock units, as described in the transaction footnotes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 06:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vazquez Chris

(Last) (First) (Middle)

919 WEST DILLON RD

(Street)

LOUISVILLE CO 80027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIODESIX INC [ BDSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		M		263	A	(1)	1,335	D
Common Stock	02/10/2026		S(2)		101	D	$10.0841(3)	1,234	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/09/2026		M			28	(4)	(4)	Common Stock	28	$0	0	D
Restricted Stock Units	(1)	02/09/2026		M			235(5)	(6)	(6)	Common Stock	235(5)	$0	234(5)	D

Explanation of Responses:

1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

3. The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. These RSUs vested in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the Reporting Person's continued service with the Issuer, and had no expiration date.

5. These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

6. These RSUs vest in a series of four successive equal annual installments measured from February 8, 2023, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.

	/s/ Robin H. Cowie as Attorney-in-Fact for Chris Vazquez	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.